Summary
Agilent Technologies, Inc. has announced a significant restructuring of its business segments, effective from November 2024, which is being formally disclosed in this 8-K filing. The company has reorganized into three new reportable segments: Life Sciences and Diagnostics Markets, Agilent CrossLab, and Applied Markets. This change is driven by a strategy to enhance market focus and customer centricity. Investors should note that this filing primarily serves to provide recast financial information for the company's Annual Report on Form 10-K for the year ended October 31, 2024, to reflect these new segment structures. It does not introduce new financial results or update the Management's Discussion and Analysis for events after the 10-K filing date. For the most current financial performance and forward-looking information, investors are directed to Agilent's subsequent Quarterly Report on Form 10-Q for the period ended January 31, 2025, and other SEC filings.
Key Highlights
- 1Agilent Technologies has reorganized its business segments to align with a market-focused, customer-centric strategy.
- 2The company now operates under three reportable segments: Life Sciences and Diagnostics Markets, Agilent CrossLab, and Applied Markets.
- 3The new Life Sciences and Diagnostics Markets segment combines former Diagnostics and Genomics with specific instrument platforms.
- 4The Agilent CrossLab segment now includes chemistries, supplies, laboratory automation, and software from previous segments.
- 5The Applied Markets segment comprises the remaining divisions, including gas chromatography, mass spectrometry, and spectroscopy.
- 6This 8-K filing provides recast information for Agilent's 2024 10-K to reflect these segment changes.
- 7Investors are advised to consult the most recent 10-Q filing for current financial performance and updates beyond the 10-K.